CompletedPhase 3

Treatment of Vasomotor Symptoms in Korean Post Menopausal Women

South Korea90 participantsStarted 2004-07

Plain-language summary

Study to demonstrate that the therapeutic efficacy of Angeliq® is better than placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and tolerability of Angeliq.

Who can participate

Age range45 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Postmenopausal Korean women suffering from hot flushes Exclusion Criteria: * Standard exclusion criteria for HRT clinical trials had to be obeyed, including current or history of hormone dependent malignant disease, thromboembolic disorders, abnormal cervical smear, undiagnosed vaginal bleeding.

What they're measuring

Hot flush (frequency and severity)

Timeframe: Daily in pre-treatment and treatment period

Trial details

NCT IDNCT00651599

SponsorBayer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Vasomotor Symptoms trials